Anixa Debt To Equity from 2010 to 2024

ANIX Stock  USD 3.31  0.01  0.30%   
Anixa Biosciences Debt To Equity yearly trend continues to be fairly stable with very little volatility. Debt To Equity is likely to outpace its year average in 2024. Debt To Equity is a measure of a company's financial leverage calculated by dividing its total liabilities by stockholders' equity, indicating the proportion of equity and debt the company is using to finance its assets. View All Fundamentals
 
Debt To Equity  
First Reported
2010-12-31
Previous Quarter
0.001821
Current Value
0.001912
Quarterly Volatility
1.42243947
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Anixa Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Anixa Biosciences' main balance sheet or income statement drivers, such as Interest Expense of 216.9 K, Selling General Administrative of 4.2 M or Total Revenue of 229.4 K, as well as many indicators such as Price To Sales Ratio of 861, Dividend Yield of 0.0 or PTB Ratio of 4.39. Anixa financial statements analysis is a perfect complement when working with Anixa Biosciences Valuation or Volatility modules.
  
Check out the analysis of Anixa Biosciences Correlation against competitors.
For more information on how to buy Anixa Stock please use our How to Invest in Anixa Biosciences guide.

Latest Anixa Biosciences' Debt To Equity Growth Pattern

Below is the plot of the Debt To Equity of Anixa Biosciences over the last few years. It is a measure of a company's financial leverage calculated by dividing its total liabilities by stockholders' equity, indicating the proportion of equity and debt the company is using to finance its assets. Anixa Biosciences' Debt To Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Anixa Biosciences' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 0.01 %10 Years Trend
Pretty Stable
   Debt To Equity   
       Timeline  

Anixa Debt To Equity Regression Statistics

Arithmetic Mean(0.20)
Geometric Mean0.01
Coefficient Of Variation(724.85)
Mean Deviation0.73
Median0.01
Standard Deviation1.42
Sample Variance2.02
Range7.1041
R-Value0.15
Mean Square Error2.13
R-Squared0.02
Significance0.59
Slope0.05
Total Sum of Squares28.33

Anixa Debt To Equity History

2024 0.001912
2023 0.001821
2021 0.001584
2020 0.001112
2013 0.0063
2012 -1.67
2011 -4.21

About Anixa Biosciences Financial Statements

Anixa Biosciences investors use historical fundamental indicators, such as Anixa Biosciences' Debt To Equity, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Anixa Biosciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Anixa Stock Analysis

When running Anixa Biosciences' price analysis, check to measure Anixa Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Anixa Biosciences is operating at the current time. Most of Anixa Biosciences' value examination focuses on studying past and present price action to predict the probability of Anixa Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Anixa Biosciences' price. Additionally, you may evaluate how the addition of Anixa Biosciences to your portfolios can decrease your overall portfolio volatility.